Symcel appoints new board members
Partnership to validate clinical antimicrobial susceptibility testing
Symcel expands staff to promote clinical market growth
Symcel secures Horizon 2020 funding
Jesper Ericsson appointed CEO of SymCel
Symcel and Colzyx partner to test 25 novel, first-in-kind collagen VI-derived antimicrobial peptides with calScreener
SymCel, TiKa Diagnostics and St George’s University partner to use calScreener in antimicrobial susceptibility testing
Symcel secures Phase I Horizon 2020 grant
SymCel’s technology opens up new research avenues in oncology, diagnostics and anti-tumour drug development
Microcalimeter technology advances real-time cellular bioenergetics measurements
SymCel launches commercial label-free cell based assay
